(Q37776145)

23 August 2017

1 reference

title

Developing an effective breast cancer vaccine (English)

1 reference

23 August 2017

Developing an Effective Breast Cancer Vaccine (English)

1 reference

https://api.crossref.org/works/10.1177/107327481001700307

11 June 2024

1 reference

Hatem Soliman

1

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20664516

11 June 2024

publication date

1 July 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

17

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

183-190

1 reference

Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Tumor vaccines for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Breast cancer vaccines: promise for the future or pipe dream?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Translational Research Working Group developmental pathway for immune response modifiers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

A clinical development paradigm for cancer vaccines and related biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Cancer vaccines for established cancer: how to make them better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Reengineering dendritic cell-based anti-cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

TRICOM vector based cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Peptide epitope identification for tumor-reactive CD4 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Challenges in the development of effective peptide vaccines for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Creating immune privilege: active local suppression that benefits friends, but protects foes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

T cell apoptosis by tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Arginase: an emerging key player in the mammalian immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Twelve immunotherapy drugs that could cure cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700307

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

21 January 2018

8

1 reference

https://api.crossref.org/works/10.1177/107327481001700307

Glycoprotein tumor antigens for immunotherapy of breast cancer.

11 June 2024

26

1 reference

https://api.crossref.org/works/10.1177/107327481001700307

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

11 June 2024

33

1 reference

https://api.crossref.org/works/10.1177/107327481001700307

Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine

11 June 2024

34

1 reference

https://api.crossref.org/works/10.1177/107327481001700307

Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results

11 June 2024

37

1 reference

https://api.crossref.org/works/10.1177/107327481001700307

Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity

11 June 2024

55

1 reference

https://api.crossref.org/works/10.1177/107327481001700307

11 June 2024

Identifiers

0 references

1 reference